Osteoporosis
Conditions
Brief summary
* Collection of epidemiological data * Biological assessment as part of routine care. * Measurement of the Hurst coefficient at D0 * Measurement of bone density and TBS on D0 * Zoledronic acid infusion the month following inclusion * phone call at 1 month (observance of zoledronic acid) * Measurement of bone density, calculation of the Hurst coefficient at M12
Interventions
DIAGNOSTIC_TESTBone mineral analyser
high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
Sponsors
University Hospital, Rouen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Women \< 85 years old * Postmenopausal women (amenorrhea for more than 12 months), a confirmation diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit). * Post-menopausal osteoporosis with one or more severe fractures (upper end of the humerus, femur, or tibia; 3 adjacent ribs; lower end of the femur; thoracic or lumbar spine; pelvis), or T score \<-3 which justifies setting up a bisphosphonate treatment * Affiliated to social security
Exclusion criteria
* Contraindication to zoledronic acid (allergy to the product, creatinine clearance \<35 ml / min, hypocalcemia, open and unhealed lesions of the soft tissues of the mouth) * Hormone replacement therapy taken in the last 12 months * Osteoprotective treatment (bisphosphonates, teriparatide, raloxifene, strontium ralenate or denosumab) taken in the last 12 months * Secondary osteoporosis: hyperthyroidism, hyperparathyroidism, long-term corticosteroid therapy, hypercorticism, hypogonadism, treatment with anti aromatases / LHRH analogues, neoplastic pathology (solid or hemopathy) * History of bilateral wrist or femur fracture * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curatorship * Patient participating in another trial / having participated in another trial within 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hurst coefficient | Day 0 | measured by the BMA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hurst coefficient | Month 12 | measured by the BMA |
| bone texture parameters | Day 0 | bone texture parameters measured by Trabecular Bone Score |
| Bone mineral density | Day 0 | Bone mineral density measured by DXA scan |
Outcome results
None listed